A Phase 3 interventional study of Sotagliflozin (SAR439954) and Glimepiride in Type 2 Diabetes Mellitus, sponsored by Lexicon Pharmaceuticals. Completed at 142 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-11.
Sponsored by Lexicon Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. sotagliflozin · Diabetes Mellitus, Type 2.
Among the 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2, this one is the 3rd largest by enrollment, is one of 9 that started in 2017, is one of 13 in phase 3, and was the 17th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Baylor Research Institute · Sites in United States
Ages 18–84
Allied Hospital Faisalabad · Sites in Pakistan
Ages 30–65
AdventHealth Translational Research Institute · Sites in United States
Ages 18–40 · Healthy volunteers
By country, each count listing its studies:
sotagliflozin: first FDA approval 2023 (INPEFA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 9 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 954 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 208 across the 28 interventional studies. Of the 25 that completed or were terminated, 13 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 28 have an industry lead sponsor. The 5 most frequent:
Lexicon Pharmaceuticals is the lead sponsor of 61 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 15 (83%) have results posted.
17 studies in Diabetes Mellitus, Type 2 by Lexicon Pharmaceuticals: none open now, none under way, none of them phase 3. Of 17 finished, 13 (76%) have results posted.
Among the 17 studies in Diabetes Mellitus, Type 2 by Lexicon Pharmaceuticals, this one is the 3rd largest by enrollment, is one of 7 that started in 2017, is one of 11 in phase 3, and was the 14th registered.
Lexicon Pharmaceuticals’s Diabetes Mellitus, Type 2 studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Among Lexicon Pharmaceuticals’s 17 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To demonstrate the non-inferiority of Sotagliflozin 400 milligrams (mg) compared to Glimepiride on hemoglobin A1c (HbA1c) reduction at Week 52 in participants with Type 2 Diabetes (T2D) who have inadequate glycemic control with metformin.
Secondary Objectives:
To demonstrate the superiority of Sotagliflozin 400 mg compared to Glimepiride on change in body weight, systolic blood pressure (SBP) in participants with baseline SBP ≥130 millimeter of mercury (mmHg), SBP in all participants, and proportion of participants with at least 1 documented symptomatic hypoglycemic event (≤70 milligrams per deciliter [mg/dL]).
Up to 58 weeks, including a Screening Period consisting of a Screening phase of up to 2 weeks, a 2-week single-blind placebo Run-in phase, a 52-week double-blind Treatment Period, and a 2-week post-treatment Follow-up period to collect safety information.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a Participants potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Following a 2-week run-in period, two Sotagliflozin 200 mg, tablets, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
Drug: Sotagliflozin (SAR439954) · Drug: Metformin · Drug: Placebo
Following a 2-week run-in period, one Sotagliflozin 200 mg, tablet and one Sotagliflozin-matching placebo tablet, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
Drug: Sotagliflozin (SAR439954) · Drug: Metformin · Drug: Placebo
Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets, and combination of two Glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
Drug: Glimepiride · Drug: Metformin · Drug: Placebo
Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
Drug: Metformin · Drug: Placebo
Pharmaceutical form: tablet Route of administration: oral
Pharmaceutical form: capsule Route of administration: oral
Pharmaceutical form: tablet Route of administration: oral
Pharmaceutical form: tablet Route of administration: oral
Pharmaceutical form: capsule Route of administration: oral
Change From Baseline in Hemoglobin A1c at Week 52
An analysis of covariance (ANCOVA) model was used for the analysis.
Time frame: Baseline, Week 52
Change From Baseline in Hemoglobin A1c at Week 26
An ANCOVA model was used for the analysis.
Time frame: Baseline, Week 26
Change From Baseline in Body Weight at Week 26 and 52
An ANCOVA model was used for the analysis.
Time frame: Baseline, Week 26, Week 52
Change From Baseline in Systolic Blood Pressure (SBP) for Participants With SBP ≥130 mmHg at Week 12
An ANCOVA model was used for the analysis.
Time frame: Baseline, Week 12
Change From Baseline in Systolic Blood Pressure (SBP) for All Participants at Week 12
An ANCOVA model was used for the analysis.
Time frame: Baseline, Week 12
Percentage of Participants With At Least One Documented Symptomatic Hypoglycemic Event
Documented symptomatic hypoglycemia includes the typical symptoms of hypoglycemia (increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, and/or coma) and plasma glucose ≤ 70 mg/dL (3.9 mmol/L).
Time frame: Up to Week 52
Percentage of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.
Time frame: Up to Week 52
Percentage of Participants With Hypoglycemic Events
Percentage of participants with hypoglycemic events are reported for the following 3 categories: Any hypoglycemia (as reported in the Electronic Case Report Form); Documented symptomatic hypoglycemia \[typical symptoms of hypoglycemia (increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, and/or coma) and plasma glucose ≤ 70 mg/dL (3.9 mmol/L)\]; Severe \[an event requiring assistance of another person to actively administer carbohydrate, glucagon, intravenous glucose or other resuscitative actions\] or documented symptomatic hypoglycemia \[typical symptoms of hypoglycemia and plasma glucose ≤ 70 mg/dL\].
Time frame: Up to Week 52
Participants took part in the study at 138 investigative sites in United States, Bulgaria, Hungary, and Slovakia from 01 December 2017 to 06 September 2019.
| Milestone | Placebo | Sotagliflozin 400 mg | Sotagliflozin 200 mg | Glimepiride |
|---|---|---|---|---|
| Started | 159 | 317 | 160 | 318 |
| Completed | 125 | 266 | 128 | 270 |
| Not completed | 34 | 51 | 32 | 48 |
| Withdrew: Adverse event | 6 | 4 | 1 | 3 |
| Withdrew: Poor compliance to protocol | 0 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 2 | 1 | 2 |
| Withdrew: At the participant's own request | 20 | 26 | 14 | 23 |
| Withdrew: Reason not specified | 6 | 18 | 16 | 19 |
An analysis of covariance (ANCOVA) model was used for the analysis.
| percentage of HbA1c | Placebo | Sotagliflozin 400 mg | Sotagliflozin 200 mg | Glimepiride |
|---|---|---|---|---|
| Change From Baseline in Hemoglobin A1c at Week 52 | -0.40 ± 0.187 | -0.65 ± 0.101 | -0.49 ± 0.114 | -0.61 ± 0.093 |
An ANCOVA model was used for the analysis.
| percentage of HbA1c | Placebo | Sotagliflozin 400 mg | Sotagliflozin 200 mg | Glimepiride |
|---|---|---|---|---|
| Change From Baseline in Hemoglobin A1c at Week 26 | -0.41 ± 0.097 | -0.77 ± 0.076 | -0.61 ± 0.098 | -1.02 ± 0.075 |
An ANCOVA model was used for the analysis.
| kilogram (kg) | Placebo | Sotagliflozin 400 mg | Sotagliflozin 200 mg | Glimepiride |
|---|---|---|---|---|
| Change at Week 26 | -1.26 ± 0.329 | -2.75 ± 0.257 | -2.24 ± 0.336 | 0.70 ± 0.256 |
| Change at Week 52 | -0.47 ± 1.406 | -2.64 ± 0.503 | -1.74 ± 0.707 | 0.94 ± 0.452 |
An ANCOVA model was used for the analysis.
| mmHg | Placebo | Sotagliflozin 400 mg | Sotagliflozin 200 mg | Glimepiride |
|---|---|---|---|---|
| Change From Baseline in Systolic Blood Pressure (SBP) for Participants With SBP ≥130 mmHg at Week 12 | -5.34 ± 1.451 | -8.03 ± 1.064 | -9.12 ± 1.466 | -3.86 ± 1.081 |
An ANCOVA model was used for the analysis.
| mmHg | Placebo | Sotagliflozin 400 mg | Sotagliflozin 200 mg | Glimepiride |
|---|---|---|---|---|
| Change From Baseline in Systolic Blood Pressure (SBP) for All Participants at Week 12 | -2.64 ± 1.013 | -4.70 ± 0.791 | -4.77 ± 1.033 | -0.68 ± 0.795 |
Documented symptomatic hypoglycemia includes the typical symptoms of hypoglycemia (increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, and/or coma) and plasma glucose ≤ 70 mg/dL (3.9 mmol/L).
| percentage of participants | Placebo | Sotagliflozin 400 mg | Sotagliflozin 200 mg | Glimepiride |
|---|---|---|---|---|
| Percentage of Participants With At Least One Documented Symptomatic Hypoglycemic Event | 0.63 | 1.26 | 3.75 | 16.67 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.
| percentage of participants | Placebo | Sotagliflozin 400 mg | Sotagliflozin 200 mg | Glimepiride |
|---|---|---|---|---|
| Percentage of Participants With Adverse Events (AEs) | 57.2 | 59.9 | 56.6 | 49.2 |
Percentage of participants with hypoglycemic events are reported for the following 3 categories: Any hypoglycemia (as reported in the Electronic Case Report Form); Documented symptomatic hypoglycemia \[typical symptoms of hypoglycemia (increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, and/or coma) and plasma glucose ≤ 70 mg/dL (3.9 mmol/L)\]; Severe \[an event requiring assistance of another person to actively administer carbohydrate, glucagon, intravenous glucose or other resuscitative actions\] or documented symptomatic hypoglycemia \[typical symptoms of hypoglycemia and plasma glucose ≤ 70 mg/dL\].
| percentage of participants | Placebo | Sotagliflozin 400 mg | Sotagliflozin 200 mg | Glimepiride |
|---|---|---|---|---|
| Any hypoglycemia | 2.5 | 4.1 | 6.3 | 25.9 |
| Documented symptomatic hypoglycemia | 0.6 | 1.3 | 3.8 | 16.7 |
| Severe or documented symptomatic hypoglycemia | 0.6 | 1.3 | 3.8 | 16.7 |
Collected over First dose of study drug to last dose of study drug (up to 52 weeks) + 2 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 2/159 (1.3%) | 11/159 (6.9%) | 30/159 (18.9%) |
| Sotagliflozin 400 mg | 1/317 (0.3%) | 17/317 (5.4%) | 49/317 (15.5%) |
| Sotagliflozin 200 mg | 0/159 (0%) | 11/159 (6.9%) | 21/159 (13.2%) |
| Glimepiride | 2/317 (0.6%) | 14/317 (4.4%) | 22/317 (6.9%) |
| Event | Placebo | Sotagliflozin 400 mg | Sotagliflozin 200 mg | Glimepiride |
|---|---|---|---|---|
| Non-cardiac chest painGeneral disorders | 2/159 | 1/317 | 0/159 | 0/317 |
| PneumoniaInfections and infestations | 0/159 | 0/317 | 1/159 | 2/317 |
| Acute left ventricular failureCardiac disorders | 1/159 | 1/317 | 0/159 | 0/317 |
| Angina pectorisCardiac disorders | 1/159 | 0/317 | 0/159 | 0/317 |
| Angina unstableCardiac disorders | 1/159 | 0/317 | 0/159 | 0/317 |
| Atrial fibrillationCardiac disorders | 0/159 | 0/317 | 1/159 | 0/317 |
| Supraventricular tachycardiaCardiac disorders | 1/159 | 0/317 | 0/159 | 0/317 |
| DeathGeneral disorders | 1/159 | 0/317 | 0/159 | 0/317 |
| Influenza like illnessGeneral disorders | 1/159 | 0/317 | 0/159 | 0/317 |
| CholelithiasisHepatobiliary disorders | 0/159 | 0/317 | 1/159 | 0/317 |
| Event | Placebo | Sotagliflozin 400 mg | Sotagliflozin 200 mg | Glimepiride |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 11/159 | 14/317 | 8/159 | 7/317 |
| HeadacheNervous system disorders | 11/159 | 14/317 | 7/159 | 12/317 |
| Vulvovaginal mycotic infectionInfections and infestations | 2/159 | 19/317 | 6/159 | 2/317 |
| HyperglycaemiaMetabolism and nutrition disorders | 8/159 | 5/317 | 2/159 | 2/317 |
The randomized population included any participant who had been allocated to a randomized treatment.
| Age, Continuous(years) | Placebo | Sotagliflozin 400 mg | Sotagliflozin 200 mg | Glimepiride | Total |
|---|---|---|---|---|---|
| Mean | 58.8 ± 11.2 | 59.7 ± 10.4 | 58.6 ± 9.9 | 59.8 ± 9.6 | 59.4 ± 10.2 |
| Sex: Female, Male(Participants) | Placebo | Sotagliflozin 400 mg | Sotagliflozin 200 mg | Glimepiride | Total |
|---|---|---|---|---|---|
| Female | 77 | 157 | 75 | 143 | 452 |
| Male | 82 | 160 | 85 | 175 | 502 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Sotagliflozin 400 mg | Sotagliflozin 200 mg | Glimepiride | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 48 | 85 | 53 | 111 | 297 |
| Not Hispanic or Latino | 110 | 230 | 106 | 207 | 653 |
| Unknown or Not Reported | 1 | 2 | 1 | 0 | 4 |
| Race (NIH/OMB)(Participants) | Placebo | Sotagliflozin 400 mg | Sotagliflozin 200 mg | Glimepiride | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 | 2 |
| Asian | 3 | 5 | 3 | 4 | 15 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 | 0 | 4 |
| Black or African American | 13 | 34 | 19 | 36 | 102 |
| White | 141 | 269 | 136 | 277 | 823 |
| More than one race | 1 | 3 | 0 | 0 | 4 |
| Unknown or Not Reported | 0 | 4 | 0 | 0 | 4 |
| Region of Enrollment(participants) | Placebo | Sotagliflozin 400 mg | Sotagliflozin 200 mg | Glimepiride | Total |
|---|---|---|---|---|---|
| Bulgaria | 7 | 17 | 5 | 16 | 45 |
| Hungary | 22 | 48 | 24 | 42 | 136 |
| Slovakia | 12 | 28 | 10 | 30 | 80 |
| United States | 118 | 224 | 121 | 230 | 693 |
| Hemoglobin A1c (HbA1c)(percentage of HbA1c) | Placebo | Sotagliflozin 400 mg | Sotagliflozin 200 mg | Glimepiride | Total |
|---|---|---|---|---|---|
| Mean | 8.12 ± 0.73 | 8.09 ± 0.78 | 8.11 ± 0.86 | 8.07 ± 0.79 | 8.09 ± 0.79 |
| Systolic Blood Pressure (SBP)(millimeter of mercury (mmHg)) | Placebo | Sotagliflozin 400 mg | Sotagliflozin 200 mg | Glimepiride | Total |
|---|---|---|---|---|---|
| Mean | 133.23 ± 14.90 | 133.17 ± 14.37 | 132.78 ± 13.29 | 134.66 ± 14.43 | 133.61 ± 14.30 |
Showing the first 100 of 142 sites across 4 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com
Ran from Dec 2017 to primary completion in Aug 2019, 20 months.
Results were first posted in May 2021, 1 year 9 months after primary completion. A results delay was requested in May 2020.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 20 months is close to that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotagliflozin